Obstructive Sleep Apnea: Symptoms, Diagnosis, and Treatment

What Is Obstructive Sleep Apnea?

Obstructive sleep apnea occurs when the muscles that normally keep the pharyngeal airway open relax during sleep, allowing soft tissue to collapse inward and block airflow for 10 seconds or longer. Each blockage is called an apnea; a partial blockage reducing airflow by at least 30% is called a hypopnea. The Apnea-Hypopnea Index (AHI) counts these events per hour of sleep and defines severity: mild (AHI 5, 14), moderate (AHI 15, 29), and severe (AHI 30+) [1].

The obstruction itself is usually multi-level. Anatomical contributors include a narrow oropharynx, enlarged tonsils, a retrognathic mandible, and excess parapharyngeal fat. Each apnea ends with a cortical arousal that fragments sleep architecture, reduces slow-wave and REM sleep, and produces the characteristic non-restorative sleep and excessive daytime sleepiness that patients describe [2].

OSA is not simply snoring. Snoring reflects turbulent airflow; OSA involves complete or near-complete cessation of airflow, repeated hypoxemia, and autonomic surges that raise nocturnal blood pressure. The distinction matters because OSA drives measurable end-organ damage over years, while primary snoring does not carry the same cardiovascular burden [3].

How Common Is OSA, and Who Is at Risk?

A 2019 Lancet Respiratory Medicine analysis estimated that 936 million adults aged 30, 69 worldwide have OSA with an AHI of 5 or more, and 425 million have moderate-to-severe disease (AHI 15+) [4]. In the United States, the Wisconsin Sleep Cohort found OSA prevalence of 9% in women and 24% in men using an AHI-plus-symptoms definition, numbers that have roughly doubled since the cohort's 1993 baseline due to rising obesity rates [5].

Key risk factors include:

• Obesity. A body mass index above 30 is the strongest modifiable risk factor. For every one-unit increase in BMI, AHI rises by approximately 3 events per hour in population data.
• Male sex. Men are 2, 3 times more likely to have OSA than premenopausal women; after menopause, the sex ratio narrows substantially.
• Age. Prevalence rises steeply after age 40 and peaks in the sixth and seventh decades.
• Craniofacial anatomy. A retrognathic mandible, high-arched palate, or macroglossia increases pharyngeal collapsibility independent of weight.
• Family history. First-degree relatives of OSA patients have approximately 1.5 to 2 times the population-level risk, reflecting heritable anatomy and ventilatory control patterns [6].
• Alcohol and sedatives. Both reduce upper-airway muscle tone and prolong apnea duration.

Post-menopausal women deserve special attention. Declining progesterone (which normally stimulates upper-airway dilator muscles) and estrogen combine to raise OSA risk threefold compared with premenopausal women of the same BMI [7].

Recognizing the Symptoms

The classic triad is loud snoring, witnessed apneas, and excessive daytime sleepiness. Bed partners often notice the episodic silence that follows a crescendo snore, ended by a gasping or choking arousal. Patients themselves may report waking with a dry mouth, morning headaches (from nocturnal hypercapnia), and the sense that sleep was not restorative regardless of total hours spent in bed [8].

Daytime symptoms extend beyond sleepiness. Cognitive slowing, irritability, reduced concentration, and depressed mood all appear at higher rates in OSA compared with controls, and the severity tracks with AHI in several large cross-sectional studies. The Epworth Sleepiness Scale score above 10 is a validated screening threshold, but roughly 30% of patients with moderate or severe OSA report normal Epworth scores, making subjective sleepiness alone an unreliable filter [9].

OSA also overlaps heavily with other sleep disorders. Chronic insomnia co-occurs in 30 to 50% of OSA patients, a combination sometimes labeled "COMISA" (comorbid insomnia and sleep apnea). Restless legs syndrome (RLS) affects approximately 6 to 9% of the general population [10] and shares risk factors with OSA including iron deficiency and dopaminergic dysregulation. Periodic limb movement disorder (PLMD), in which repetitive leg movements fragment sleep without the conscious urge to move that defines RLS, appears in roughly 80% of patients with RLS and also occurs independently in older adults with OSA.

Diagnosis: Home Sleep Testing vs. In-Lab Polysomnography

The American Academy of Sleep Medicine (AASM) 2017 guidelines state that in-lab attended polysomnography (PSG) is the gold standard for OSA diagnosis. PSG simultaneously records electroencephalography, electrooculography, electromyography, airflow, respiratory effort, oxygen saturation, and leg movements, allowing complete sleep staging and identification of co-occurring disorders including PLMD [11].

Home sleep apnea testing (HSAT) devices, which typically measure airflow, respiratory effort, and pulse oximetry without EEG, are AASM-approved for patients with a high pre-test probability of moderate-to-severe uncomplicated OSA and without significant cardiorespiratory comorbidities. Studies show HSAT sensitivity of roughly 79 to 90% against PSG for AHI 15+, with specificity of 87 to 93%. A negative HSAT in a clinically suspicious patient should prompt in-lab testing, because HSAT cannot stage sleep and tends to underestimate AHI by 15 to 20% in patients with severe OSA due to recording time artifact [12].

The diagnostic AHI cutoffs per AASM 2012/2017 clinical guidelines are:

• Mild OSA. AHI 5, 14 events/hour with at least one symptom (sleepiness, insomnia, fatigue, witnessed apnea, hypertension, mood disturbance, cognitive impairment, or coronary artery disease).
• Moderate OSA. AHI 15, 29 events/hour.
• Severe OSA. AHI 30+ events/hour.

The oxygen desaturation index (ODI), defined as the number of times per hour oxygen saturation drops 3% or more, is a secondary metric. An ODI above 15 per hour in the absence of a formal AHI score is clinically significant and warrants treatment consideration [13].

Cardiovascular and Metabolic Consequences of Untreated OSA

Each apnea produces a cascade: oxygen desaturation, hypercapnia, intrathoracic pressure swings (sometimes minus 80 cm H2O), sympathetic activation, and cortical arousal. Repeated over hundreds of cycles per night, these stresses translate into measurable pathology. The Sleep Heart Health Study (N=6,441) found that severe OSA was associated with an odds ratio of 1.37 for prevalent coronary artery disease and 1.58 for prevalent heart failure after adjustment for age, sex, BMI, and other covariates [14].

Systemic hypertension is the best-established cardiovascular consequence. The Wisconsin Sleep Cohort prospective data showed that an AHI of 15 or more at baseline was associated with a 3-fold increased risk of developing hypertension at the 4-year follow-up, independent of baseline weight and other confounders [5]. The 2017 ACC/AHA hypertension guidelines list OSA as a secondary cause of hypertension worthy of investigation in resistant cases.

Atrial fibrillation risk is also elevated. A Mayo Clinic analysis found OSA in 32% of patients referred for AF cardioversion, compared with 12% of matched controls, and untreated OSA roughly doubles AF recurrence after cardioversion or ablation [15].

Metabolic effects include insulin resistance that is partly independent of obesity. Intermittent hypoxia activates inflammatory pathways (NF-κB, HIF-1α) and raises cortisol and catecholamines, impairing glucose uptake. A cross-sectional analysis of the multi-center WSCS and SHHS data estimated that moderate-to-severe OSA was associated with a 40 to 50% increased odds of type 2 diabetes after BMI adjustment [16].

First-Line Treatment: CPAP Therapy

Continuous positive airway pressure remains the most effective treatment for OSA at all severity levels. CPAP delivers pressurized air (typically 4 to 20 cm H2O) through a mask interface, acting as a pneumatic splint that holds the upper airway open throughout the respiratory cycle. Fixed-pressure CPAP, auto-titrating CPAP (APAP), and bilevel positive airway pressure (BiPAP) are the three main delivery modes [17].

APAP devices use algorithms to detect flow limitation, snoring, and apneas, then adjust pressure breath-by-breath within a clinician-set range. APAP is appropriate for uncomplicated OSA without significant central apnea, Cheyne-Stokes respiration, or severe COPD. BiPAP, with separate inspiratory and expiratory pressures (IPAP/EPAP), is typically reserved for patients who cannot tolerate high fixed pressures or who have comorbid hypoventilation.

The SAVE trial (N=2,687), published in the New England Journal of Medicine in 2016, found that CPAP did not reduce the rate of cardiovascular events in OSA patients who had already experienced a cardiovascular event, compared with usual care. The mean nightly CPAP use was only 3.3 hours, below the 4-hour adherence threshold generally considered therapeutic [18]. This underscores that CPAP's cardiovascular benefits depend on adequate adherence, not merely a prescription.

Symptom benefits from CPAP are well-documented. A Cochrane systematic review (2006, updated) covering 36 randomized trials found CPAP significantly reduced Epworth Sleepiness Scale scores by a mean of 2.94 points (95% CI 2.28, 3.59) compared with control interventions, and improved objective sleepiness on the Multiple Sleep Latency Test [19]. Blood pressure reductions of 2 to 3 mmHg systolic have been consistently observed in adherent patients, with larger reductions (up to 7 mmHg) in those with severe OSA who use CPAP 6+ hours per night.

Mask fit is the single most common barrier to adherence. Nasal masks, nasal pillow masks, and full-face masks each suit different facial anatomies and mouth-breathing patterns. Patients should trial at least two mask styles before concluding CPAP is intolerable. Adding heated humidification reduces nasal dryness and raises 90-day adherence by approximately 15% in randomized data [20].

Weight Loss and Positional Therapy

Because adipose tissue in the parapharyngeal region directly compresses the airway, weight loss reliably reduces AHI. The Sleep AHEAD study embedded within the Look AHEAD trial found that an average weight loss of 10.5 kg over 1 year reduced AHI by 9.7 events/hour compared with 2.0 events/hour in the usual-care arm [21]. Complete remission (AHI <5) was achieved in 13.6% of intensive lifestyle intervention participants vs. 3.5% in usual care.

GLP-1 receptor agonists are now generating OSA-specific data. The SURMOUNT-OSA trial (Eli Lilly, 2024, N=469) showed tirzepatide 10 mg or 15 mg weekly reduced AHI by 25, 29 events/hour vs. 5, 6 events/hour with placebo at 52 weeks in patients with obesity and moderate-to-severe OSA, with 42% of tirzepatide patients achieving AHI <5 (OSA remission) [22]. Weight loss drove most of the effect, but the magnitude exceeded what the weight-loss alone regression predicted, suggesting additional mechanisms.

Positional therapy (devices that prevent supine sleeping) reduces AHI by 50% or more in patients with position-dependent OSA, defined as AHI in the supine position at least twice the non-supine AHI. Approximately 55% of OSA patients have position-dependent disease, making this a low-cost adjunct worth testing [23].

Oral Appliances and Surgical Options

Mandibular advancement devices (MADs) reposition the lower jaw forward by 5 to 10 mm, enlarging the retropalatal and retroglossal spaces. They are AASM-recommended for mild-to-moderate OSA and as CPAP alternatives in patients with moderate-to-severe OSA who cannot adhere to CPAP. A 2015 Cochrane review found MADs reduced AHI by a mean of 10, 14 events/hour vs. control, less than CPAP's average reduction of 14, 18 events/hour, but patient preference often favors MADs for tolerability [24].

Upper airway surgery has evolved considerably. Uvulopalatopharyngoplasty (UPPP), the traditional resection of redundant soft palate tissue, produces long-term AHI reduction in only about 50% of patients and is no longer a first-line surgical option per AASM guidance. Multi-level surgery combining UPPP with genioglossus advancement or hyoid myotomy achieves better outcomes in carefully selected patients.

Hypoglossal nerve stimulation (HNS), marketed as Inspire, received FDA approval in 2014 for adults with moderate-to-severe OSA (AHI 15, 65), BMI <32, CPAP intolerance, and absence of complete concentric collapse at the palate on drug-induced sleep endoscopy (DISE). The STAR trial 5-year data showed median AHI reduction from 28.9 at baseline to 6.2 at 60 months, with 75% of participants achieving a treatment response (AHI reduction >50% and AHI <20) [25].

OSA and Co-Occurring Sleep Disorders

Chronic and Acute Insomnia

Chronic insomnia, defined as difficulty initiating or maintaining sleep at least three nights per week for three months or longer, co-exists with OSA in a significant fraction of patients. The bidirectional relationship matters clinically: untreated OSA fragments sleep and can cause conditioned arousal that perpetuates insomnia, while hyperarousal from insomnia may worsen respiratory instability during sleep. Cognitive behavioral therapy for insomnia (CBT-I), the first-line treatment per AASM 2021 guidelines [26], improves both sleep initiation and CPAP adherence when delivered concurrently with CPAP titration. Acute insomnia, lasting fewer than three months and often tied to a stressor or acute illness, generally does not require CBT-I but may benefit from brief behavioral interventions to prevent chronification.

Restless Legs Syndrome

Restless legs syndrome is characterized by an uncontrollable urge to move the legs, worse at rest, worst in the evening, and partially or fully relieved by movement. The IRLSSG diagnostic criteria require all four features. RLS affects 6 to 9% of adults, but prevalence rises to 20 to 30% in patients with end-stage renal disease and in pregnancy [10]. First-line pharmacotherapy per 2012 AASM guidelines and 2013 IRLSSG recommendations includes low-dose dopamine agonists (pramipexole 0.125 to 0.5 mg, ropinirole 0.25 to 1 mg taken 1 to 3 hours before bed) or alpha-2-delta calcium channel ligands (gabapentin enacarbil 600 mg, pregabalin 150 to 300 mg). Serum ferritin below 75 ng/mL should trigger oral iron supplementation, as iron is the rate-limiting cofactor for dopamine synthesis [27].

Periodic Limb Movement Disorder

Periodic limb movement disorder involves rhythmic, stereotyped leg movements during sleep (0.5, 10 seconds each, spaced 20, 40 seconds apart) with a PLMS index of 15 or more per hour. Unlike RLS, PLMD occurs without a conscious urge. PSG is required for diagnosis because HSAT devices do not capture leg EMG. PLMD is treated when movements produce significant arousals and insomnia; the same dopamine agonists used for RLS are effective [28].

A Clinical Decision Framework for the Newly Diagnosed OSA Patient

The following stepwise approach integrates severity, symptoms, and comorbidities:

Step 1. Establish AHI and symptoms. Use PSG for suspected COMISA, suspected PLMD, or high cardiorespiratory comorbidity burden. Use HSAT for uncomplicated moderate-to-severe clinical suspicion.

Step 2. Stratify treatment by AHI and anatomy. AHI 5, 14 with minimal symptoms: positional therapy or MAD as first options. AHI 5, 14 with significant cardiovascular disease or sleepiness: CPAP. AHI 15+: CPAP first; MAD for CPAP-intolerant patients. AHI 15, 65 with CPAP failure and confirmed anatomy: evaluate for HNS.

Step 3. Address modifiable risk factors in parallel. Prescribe structured weight-loss intervention for BMI >27. Eliminate alcohol within 4 hours of bedtime. Screen serum ferritin if RLS is present.

Step 4. Manage co-occurring sleep disorders. Refer to CBT-I for concurrent chronic insomnia. Treat PLMD when PLMS index >15 with arousals. Reassess OSA AHI after 10% or more weight loss because AHI may fall below treatment threshold.

Step 5. Monitor adherence and outcomes. Download CPAP usage data at 30 days and 90 days. Residual AHI above 5 on CPAP data suggests mask leak, positional issue, or central apnea emergence; the last warrants switching to adaptive servoventilation after excluding systolic heart failure.

Adherence, Follow-Up, and Long-Term Management

Most insurance and Medicare coverage in the United States requires demonstrating CPAP adherence of 4 hours per night for 70% of nights over a 30-day period. Patients who do not meet this threshold may lose coverage and device rental continuation. Structured adherence support, including telemonitoring with feedback, raises 90-day adherence rates by 15 to 20% compared with standard care in randomized trials [29].

Long-term cardiovascular benefit from CPAP appears to require sustained adherence. Observational data from the Observational Study with Respect to Sleep Apnea cohort found that patients using CPAP 6 hours or more per night had cardiovascular event rates comparable to non-OSA controls over 5 years, while those using CPAP fewer than 4 hours per night had event rates similar to untreated OSA patients [30].

Annual follow-up visits should reassess weight (and recalculate whether AHI has changed), review current mask comfort, download compliance data, and screen for RLS, PLMD, and insomnia symptoms that may have emerged or worsened. Patients who achieve 15% or more weight loss through bariatric surgery or GLP-1 pharmacotherapy should undergo repeat PSG or HSAT to determine whether CPAP remains necessary, since AHI may fall below 5 and treatment can sometimes be discontinued.